{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:49:04Z","timestamp":1785426544069,"version":"3.56.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejogrb.2019.10.011","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:48:20Z","timestamp":1571140100000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Controversial association between polycystic ovary syndrome and breast cancer"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9409-5466","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Subtil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c2ngela","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-2667","authenticated-orcid":false,"given":"Margarida","family":"Figueiredo-Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2019.10.011_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5468\/ogs.2016.59.5.367","article-title":"The association between polycystic ovary syndrome and breast cancer: a meta-analysis","volume":"59","author":"Shobeiri","year":"2016","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0010","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/humupd\/dmu012","article-title":"Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"20","author":"Barry","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2014.11.012","article-title":"Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study","volume":"136","author":"Gottschau","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0020","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3109\/09513590.2010.490607","article-title":"Oncological repercussions of polycystic ovary syndrome","volume":"26","author":"de Fran\u00e7a Neto","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0025","article-title":"Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003\u20132008","volume":"207","author":"Okoroh","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0040","series-title":"Evidence-based methodology workshop on polycystic ovary syndrome","author":"National Institutes of Health","year":"2012"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0045","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod (Oxford, Engl)"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijerph15112589","article-title":"Geographical prevalence of polycystic ovary syndrome as determined by region and race\/ethnicity","volume":"15","author":"Wolf","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0055","article-title":"Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003\u20132008","volume":"207","author":"Okoroh","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0060","first-page":"2434","article-title":"A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain","volume":"85","author":"Asunci\u00f3n","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0065","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod (Oxford, Engl)"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0070","doi-asserted-by":"crossref","first-page":"96351","DOI":"10.18632\/oncotarget.19180","article-title":"The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis","volume":"8","author":"Ding","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsbmb.2003.10.011","article-title":"The proliferative effects of 5-androstene-3\u03b2,17\u03b2-diol and 5\u03b1-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines","volume":"88","author":"Aspinall","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/bcr2413","article-title":"Androgens and the breast","volume":"11","author":"Dimitrakakis","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/humrep\/des042","article-title":"Evaluating the association between endometrial cancer and polycystic ovary syndrome","volume":"27","author":"Haoula","year":"2012","journal-title":"Hum Reprod (Oxford, Engl)"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1472-6483(10)60175-7","article-title":"Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review","volume":"19","author":"Chittenden","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/09513590.2012.730575","article-title":"Is polycystic ovary syndrome, a state of relative estrogen excess, a real risk factor for estrogen-dependant malignancies?","volume":"29","author":"Fanta","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-Z","article-title":"Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa","volume":"79","author":"Anderson","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40738-016-0029-2","article-title":"Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review","volume":"2","author":"Harris","year":"2016","journal-title":"Fertil Res Pract"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jnci\/djn415","article-title":"Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women","volume":"101","author":"Gunter","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0115","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/ijc.31249","article-title":"Circulating anti-M\u00fcllerian hormone and breast cancer risk: a study in ten prospective cohorts","volume":"142","author":"Ge","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0120","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/bjc.1997.289","article-title":"Selected medical conditions and risk of breast cancer","volume":"75","author":"Talamini","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0125","first-page":"875","article-title":"Metabolic disorders and breast cancer risk (United States)","volume":"12","author":"Baron","year":"2001","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1634\/theoncologist.2014-0311","article-title":"A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast Cancer in women with polycystic ovary syndrome","volume":"20","author":"Shen","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00006254-200106000-00022","article-title":"Androgens in postmenopausal women: production, possible role, and replacement options","volume":"56","author":"Lobo","year":"2001","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/oxfordjournals.aje.a113184","article-title":"Breast cancer incidence in women with a history of progesterone deficiency","volume":"114","author":"Cowan","year":"1981","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsbmb.2007.05.012","article-title":"Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk","volume":"106","author":"Hankinson","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ijc.20582","article-title":"Serum testosterone levels and breast cancer recurrence","volume":"113","author":"Berrino","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0155","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1055-9965.EPI-10-1240","article-title":"Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes","volume":"20","author":"Emond","year":"2011","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0160","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jnci\/djr031","article-title":"Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers","volume":"103","author":"Farhat","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0165","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.2011.254","article-title":"Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies","volume":"105","author":"Key","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0170","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/ERC-18-0429","article-title":"Androgen excess in breast cancer development: implications for prevention and treatment","author":"Secreto","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0175","first-page":"606","article-title":"Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies","volume":"94","author":"The Endogenous Hormones and Breast Cancer Collaborative Group","year":"2002","journal-title":"CancerSpectrum Knowl Environ"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0180","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.2006.09.0118","article-title":"Plasma testosterone and prognosis of postmenopausal breast cancer patients","volume":"25","author":"Micheli","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0185","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1055-9965.EPI-05-0976","article-title":"The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women","volume":"15","author":"Tworoger","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0190","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/jnci\/djj376","article-title":"Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women","volume":"98","author":"Eliassen","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0195","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.fertnstert.2009.10.012","article-title":"Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome)","volume":"94","author":"Brinton","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0200","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/ijc.21730","article-title":"Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort","volume":"118","author":"Rinaldi","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0205","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jnci\/dji132","article-title":"Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"97","author":"Kaaks","year":"2005","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0210","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1055-9965.1032.13.6","article-title":"Plasma adrenal androgens and risk of breast cancer in premenopausal women","volume":"13","author":"Page","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0215","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/ijc.22203","article-title":"Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women","volume":"119","author":"Adly","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0220","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/jnci\/djj011","article-title":"Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the nsabp breast cancer prevention trial (P-1)","volume":"98","author":"Beattie","year":"2006","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0225","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1001\/archinte.166.14.1483","article-title":"Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women","volume":"166","author":"Tamimi","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.gme.0000232033.92411.51","article-title":"Testosterone inhibits estrogen\/progestogen-induced breast cell proliferation in postmenopausal women","volume":"14","author":"Hofling","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0235","first-page":"2250","article-title":"5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions","volume":"86","author":"Suzuki","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mce.2011.06.002","article-title":"Recent developments in antiandrogens and selective androgen receptor modulators","volume":"352","author":"Haendler","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2310\/6650.2001.34090","article-title":"Primate mammary gland insulin-like growth factor system: cellular localization and regulation by sex steroids","volume":"49","author":"Zhou","year":"2001","journal-title":"J Investig Med"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0303-7207(00)00442-1","article-title":"Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol","volume":"173","author":"Schmitt","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0255","doi-asserted-by":"crossref","first-page":"djt319","DOI":"10.1093\/jnci\/djt319","article-title":"Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis","volume":"106","author":"Vera-Badillo","year":"2014","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0260","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/modpathol.2009.159","article-title":"Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation","volume":"23","author":"Niemeier","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0265","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jsbmb.2008.12.010","article-title":"Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-\u03b1-positive and -negative breast cancer cells","volume":"113","author":"Lin","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0270","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1038\/onc.2016.432","article-title":"Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms","volume":"36","author":"Feng","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0275","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/19396368.2017.1410591","article-title":"Sex hormone binding globulin\u2014an important biomarker for predicting PCOS risk: a systematic review and meta-analysis","volume":"64","author":"Deswal","year":"2018","journal-title":"Syst Biol Reprod Med"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.bjc.6601517","article-title":"Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study","volume":"90","author":"Zeleniuch-Jacquotte","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0285","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1038\/s41598-019-41016-4","article-title":"Androgens induce invasiveness of triple negative breast cancer cells through AR\/Src\/PI3-K complex assembly","volume":"9","author":"Giovannelli","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0290","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/MCB.18.8.4471","article-title":"High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells","volume":"18","author":"Boonyaratanakornkit","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0295","doi-asserted-by":"crossref","first-page":"69520","DOI":"10.18632\/oncotarget.17846","article-title":"Oncotarget 69520 www.impactjournals.com\/oncotarget PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/epr.09.68","article-title":"Framework for a systems approach to proteomic biomarker profiling in polycystic ovary syndrome","volume":"6","author":"Atiomo","year":"2009","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2019.00203","article-title":"MicroRNAs and androgen receptor: emerging players in breast cancer","volume":"10","author":"Bandini","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0310","first-page":"1","article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study","volume":"362","author":"Iversen","year":"2018","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0315","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.contraception.2013.08.008","article-title":"Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study","volume":"88","author":"Vessey","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0320","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0325","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMe1709636","article-title":"Oral contraceptives and the small increased risk of breast cancer","volume":"377","author":"Hunter","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2017.02.002","article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners\u2019 oral contraception study","volume":"216","author":"Iversen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0335","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clbc.2012.03.004","article-title":"Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study","volume":"12","author":"Campagnoli","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0340","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0345","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/156652410792630625","article-title":"Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells","volume":"10","author":"Vazquez-Martin","year":"2010","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0350","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/er.2008-0047","article-title":"Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease","volume":"30","author":"Belfiore","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0355","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3816\/CBC.2008.n.060","article-title":"Insulin-lowering effects of metformin in women with early breast cancer","volume":"8","author":"Goodwin","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0360","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: the end of the beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0365","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.steroids.2013.04.004","article-title":"Cancer risk and PCOS","volume":"78","author":"Dumesic","year":"2013","journal-title":"Steroids"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0370","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-012-2170-x","article-title":"Metformin and breast cancer risk: a meta-analysis and critical literature review","volume":"135","author":"Col","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0375","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pds.3823","article-title":"No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK","volume":"24","author":"Kowall","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0380","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/10799893.2014.951895","article-title":"Effect of estradiol and clomiphene citrate on Erk activation in breast cancer cells","volume":"35","author":"Elloumi-Mseddi","year":"2015","journal-title":"J Recept Signal Transduct"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.1996.0002","article-title":"Risk of breast cancer in a cohort of infertile women","volume":"60","author":"Rossing","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0390","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1001\/archinte.166.22.2484","article-title":"A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer","volume":"166","author":"Terry","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0395","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jama.2016.9389","article-title":"Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer","volume":"316","author":"van den Belt-Dusebout","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0400","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41416-018-0139-1","article-title":"Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1\/2 mutation carriers","volume":"119","author":"Derks-Smeets","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0405","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/humrep\/dex027","article-title":"The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review","volume":"32","author":"Rodgers","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0410","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2018.5188","article-title":"Association between polycystic ovary syndrome and cancer risk","volume":"5","author":"Yin","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0415","first-page":"403","article-title":"Polycystic ovarian syndrome (PCOS), related symptoms\/sequelae, and breast cancer risk in a population-based case\u2013control study","volume":"27","author":"Kim","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejogrb.2019.10.011_bib0420","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/oxfordjournals.aje.a116156","article-title":"Polycystic ovaries and the risk of breast cancer","volume":"134","author":"Gammon","year":"1991","journal-title":"Am J Epidemiol"}],"container-title":["European Journal of Obstetrics &amp; Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211519304622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211519304622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:47:03Z","timestamp":1759556823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211519304622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":84,"alternative-id":["S0301211519304622"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2019.10.011","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversial association between polycystic ovary syndrome and breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2019.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}